Researchers Receive Grants from NCCN Oncology Research Program Funded through AVEO/Astellas Collaboration
Saved in:
| Title: | Researchers Receive Grants from NCCN Oncology Research Program Funded through AVEO/Astellas Collaboration |
|---|---|
| Authors: | National Comprehensive Cancer Network (NCCN) |
| Source: | Business Wire (English). 10/15/2012. |
| Abstract: | The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces funding of five new investigator-initiated studies of tivozanib, an investigational agent currently being evaluated in advanced renal cell carcinoma and other tumors. These grants were made possible through a research grant from AVEO Oncology and Astellas Pharma Inc. (Tokyo: 4503) to develop oncology research protocols and trials examining tivozanib as a single agent and in combination with other drugs in the treatment of solid tumors. [ABSTRACT FROM PUBLISHER] |
| Database: | Regional Business News |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces funding of five new investigator-initiated studies of tivozanib, an investigational agent currently being evaluated in advanced renal cell carcinoma and other tumors. These grants were made possible through a research grant from AVEO Oncology and Astellas Pharma Inc. (Tokyo: 4503) to develop oncology research protocols and trials examining tivozanib as a single agent and in combination with other drugs in the treatment of solid tumors. [ABSTRACT FROM PUBLISHER] |
|---|
